The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9.
Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland 20 N. Pine St, Baltimore, MD 21201 USA.
BMC cancer 2011;11():7.
BACKGROUND: The extracellular signal-regulated kinase-1 and 2 (ERK1/2) proteins play an important role in cancer cell proliferation and survival. ERK1/2 proteins also are important for normal cell functions. Thus, anti-cancer therapies that block all ERK1/2 signaling may result in undesirable toxicity to normal cells. As an alternative, we have used computational and biological approaches to identify low-molecular weight compounds that have the potential to interact with unique ERK1/2 docking sites and selectively inhibit interactions with substrates involved in promoting cell proliferation. METHODS: Colony formation and water soluble tetrazolium salt (WST) assays were used to determine the effects of test compounds on cell proliferation. Changes in phosphorylation and protein expression in response to test compound treatment were examined by immunoblotting and in vitro kinase assays. Apoptosis was determined with immunoblotting and caspase activity assays. RESULTS: In silico modeling was used to identify compounds that were structurally similar to a previously identified parent compound, called 76. From this screen, several compounds, termed 76.2, 76.3, and 76.4 sharing a common thiazolidinedione core with an aminoethyl side group, inhibited proliferation and induced apoptosis of HeLa cells. However, the active compounds were less effective in inhibiting proliferation or inducing apoptosis in non-transformed epithelial cells. Induction of HeLa cell apoptosis appeared to be through intrinsic mechanisms involving caspase-9 activation and decreased phosphorylation of the pro-apoptotic Bad protein. Cell-based and in vitro kinase assays indicated that compounds 76.3 and 76.4 directly inhibited ERK-mediated phosphorylation of caspase-9 and the p90Rsk-1 kinase, which phosphorylates and inhibits Bad, more effectively than the parent compound 76. Further examination of the test compound's mechanism of action showed little effects on related MAP kinases or other cell survival proteins. CONCLUSION: These findings support the identification of a class of ERK-targeted molecules that can induce apoptosis in transformed cells by inhibiting ERK-mediated phosphorylation and inactivation of pro-apoptotic proteins.
1 Originating Grant
SHAPIRO, PAUL S
1 April 2006 - 28 February 2011
NATIONAL CANCER INSTITUTE
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Jerome F Sah; Sivaprakasam Balasubramanian; Richard L Eckert; Ellen A RorkeThe Journal of biological chemistry 2004;279(13):12755-62.
Chad N Hancock; Alba Macias; Eun Kyoung Lee; Su Yeon Yu; Alexander D Mackerell; Paul ShapiroJournal of medicinal chemistry 2005;48(14):4586-95.
Coleen M Atkins; Anthony A Oliva; Ofelia F Alonso; Shaoyi Chen; Helen M Bramlett; Bing-Ren Hu; W Dalton DietrichThe European journal of neuroscience 2007;26(4):810-9.
Appears in this Publication
Author of this Publication